Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients With EGFR Wild-Type Non-Small-Cell Lung Cancer: The Never-Ending Story

被引：13
|
作者：
Gelsomino, Francesco [1 ]
Agustoni, Francesco [1 ]
Niger, Monica [1 ]
Valota, Marika [1 ]
Haspinger, Eva R. [1 ]
机构：
[1] Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, I-20133 Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 26期
关键词：
PHASE-III TRIAL; PLATINUM-BASED CHEMOTHERAPY; DOUBLE-BLIND; OPEN-LABEL; MAINTENANCE THERAPY; 1ST-LINE ERLOTINIB; 2ND-LINE TREATMENT; GEFITINIB; MULTICENTER; PLACEBO;
D O I：
10.1200/JCO.2013.50.2617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3291 / 3293
页数：3
相关论文
共 50 条
  • [1] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients With EGFR Wild-Type Non-Small-Cell Lung Cancer: The Never-Ending Story Reply
    Laurie, Scott A.
    Goss, Glenwood D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) : 3293 - 3294
  • [2] Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR
    Mitsuoka, Shigeki
    Kawaguchi, Tomoya
    Kubo, Akihito
    Isa, Shun-ichi
    Asai, Kazuhisa
    Uji, Masato
    Watanabe, Tetsuya
    Sawa, Kenji
    Yoshimoto, Naoki
    Oka, Takako
    Nakai, Toshiyuki
    Suzumura, Tomohiro
    Tanaka, Hidenori
    Matsuura, Kuniomi
    Kimura, Tatsuo
    Yoshimura, Naruo
    Kudoh, Shinzoh
    Hirata, Kazuto
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (02) : 193 - 203
  • [3] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Thomas E. Stinchcombe
    Current Treatment Options in Oncology, 2016, 17
  • [4] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Stinchcombe, Thomas E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (04)
  • [5] Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non-Small-Cell Lung Cancer
    Laurie, Scott A.
    Goss, Glenwood D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) : 1061 - 1069
  • [6] A meta-analysis of the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.
    Xu, Hongmei
    Minchella, Kaitlyn
    Zhou, Diansong
    Al-Huniti, Nidal
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
    Wang, Z.
    Wu, Y. L.
    Yang, J.
    Wang, B.
    Huang, Y.
    Zhou, Q.
    Xu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] The use of epidermal growth factor receptor tyrosine kinase inhibitors in treatment of advanced EGFR wild-type non-small cell lung cancer: A meta-analysis
    Wong, K.
    Victor, C.
    Eng, L.
    Verma, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S825 - S825
  • [9] Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment
    Schettino, Clorinda
    Bareschino, Maria Anna
    Maione, Paolo
    Rossi, Antonio
    Ciardiello, Fortunato
    Gridelli, Cesare
    CURRENT CANCER THERAPY REVIEWS, 2007, 3 (04) : 226 - 235
  • [10] Is epidermal growth factor receptor tyrosine kinase inhibitor in combination with cytotoxic chemotherapy a better treatment option for patients with EGFR-mutated non-small-cell lung cancer?
    Takahashi, Kosuke
    Saito, Hiroshi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (01) : 98 - 101
12345